Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

atorvastatin

Known as: (betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid, (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid 
A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Background and Purpose— The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations for… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2006
Highly Cited
2006
BACKGROUND Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
Background Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit… Expand
Highly Cited
2005
Highly Cited
2005
background Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2005
Highly Cited
2005
BACKGROUND Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2005
Highly Cited
2005
CONTEXT Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2005
Highly Cited
2005
BACKGROUND Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
  • figure 3
Highly Cited
2004
Highly Cited
2004
BACKGROUND Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid… Expand
  • figure 1
  • table 2
  • figure 2
  • table 3
  • figure 3
Highly Cited
2003
Highly Cited
2003
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2001
Highly Cited
2001
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study : A randomized… Expand